Find where to buy products from UK suppliers, including: distributors, industrial manufacturers, wholesalers, raw ingredients, bulk supplies and finished goods for sale.
Search for products or services, then visit the suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the USA.
| Product | Description | |
|---|---|---|
| Protein Kinase Inhibitors 1 | Protein Kinase Inhibitors 1 is a HIPK2 inhibitor with IC50 of 74 nM and Kd of 9.5 nM. Group: Pharmaceutical. CAS No. 1365986-44-2. Pack Sizes: 20 mg. Product ID: B0084-284772. Molecular formula: Custom synthesis is available. Send your inquiries for more information. |  London |
| 1,2-Dioleoyl-sn-glycerol | 1,2-Dioleoyl-sn-glycerol is an analog of the protein kinase C-activating second messenger DAG. Group: Pharmaceutical. CAS No. 24529-88-2. Pack Sizes: 100 mg. Product ID: B0084-203872. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| 17-DMAG hydrochloride | 17-DMAG hydrochloride (Alvespimycin hydrochloride) is the hydrochloride salt of alvespimycin, an analogue of the antineoplastic benzoquinone antibiotic geldanamycin. Alvespimycin binds to Hsp90, a chaperone protein that aids in the assembly, maturation and folding of proteins. Subsequently, the function of Hsp90 is inhibited, leading to the degradation and depletion of its client proteins such as kinases and transcription factors involved with cell cycle regulation and signal transduction. Group: Pharmaceutical. CAS No. 467214-21-7. Pack Sizes: 100 mg. Product ID: BBF-05796. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| [(2S,6R)-6-{N4-Benzoylcydin-1-yl}-4-tritylmorpholin-2-yl]methyl dimethyl-phosphoramidochloridate | This product is a potent inhibitor of Abl kinases and was developed for the treatment of chronic myeloid leukemia (CML). It works by blocking the activity of the Bcr-Abl fusion protein, which drives the growth of CML cells. Clinical trials have shown promising results, with high rates of complete remission and durable responses in patients with CML who were resistant or intolerant to previous treatments. Group: Pharmaceutical. CAS No. 956139-21-2. Pack Sizes: 1 g. Product ID: B2706-339313. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| 4-Chloro-5H-pyrrolo[3,2-d]pyrimidin-2-amine | 4-Chloro-5H-pyrrolo[3,2-d]pyrimidin-2-amine is a highly potent and selective protein kinase CK1ε inhibitor. Evidence suggests that this compound exhibits strong neuroprotective and anti-tumor activity, and holds great promise as a potential treatment for Alzheimer's disease and select cancers. Its unique chemical structure and mechanism of action make it an exciting candidate for further preclinical and clinical development. Group: Pharmaceutical. CAS No. 943736-58-1. Pack Sizes: 10 g. Product ID: B2699-100946. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| 5,7-Dihydrox -4'-methoxyisoflavone | Biochanin A, an O-methylated isoflavone from Trifolium pratense, inhibits protein tyrosine kinase (PTK) of epidermal growth factor receptor with IC50 values of 91.5 μM. Uses: Anti-tumorigenesis, anti-oxidation, and anti-inflammatory. Group: Pharmaceutical. CAS No. 491-80-5. Pack Sizes: 5 g. Product ID: NP1827. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Acetyl-α,β-dehydro-phenylalanine | A protein kinase C inhibitor. Group: Pharmaceutical. CAS No. 5469-45-4. Pack Sizes: 1mg; 1g; 10g. Product ID: BAT-002080. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Acteoside | Verbascoside is a bioactive polyphenol from olive oil mill wastewater with known antioxidant activity, which is a protein kinase C inhibitor. Uses: Antineoplastic; antimetastatic;antimicrobial activity. Group: Pharmaceutical. CAS No. 61276-17-3. Pack Sizes: 100 mg. Product ID: NP5345. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| AG 126 | Tyrphostins are protein tyrosine kinase inhibitors developed to inhibit cell growth through blocking the activity of certain GFRK (growth factor receptor kinases). AG 126 selectively inhibits the phosphorylation of ERK1 and ERK2 at 25-50 μM. It also inhibits the production of TNF-α (tumor necrosis factor-α), attenuating signaling through NF-κB, the induced expression of COX-2 and iNOS, and the inflammatory response in animal models. AG 126 is a poor inhibitor of epidermal GFRK with IC50 of 450 μM and platelet-derived GFRK with IC50 > 100 μM. AG 126 may represent a new approach for the therapy of inflammation. Uses: Anti- inflammation. Group: Pharmaceutical. CAS No. 118409-62-4. Pack Sizes: 100 mg. Product ID: B1370-195904. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Alectinib | Alectinib, marketed as Alecensa, is an oral drug that blocks the activity of anaplastic lymphoma kinase (ALK) and is used to treat non-small-cell lung cancer (NSCLC). Alectinib has a low potential for interactions. While it is metabolised by the liver enzyme CYP3A4, and blockers of this enzyme accordingly increase its concentrations in the body, they also decrease concentrations of the active metabolite M4, resulting in only a small overall effect. Conversely, CYP3A4 inducers decrease alectinib concentrations and increase M4 concentrations. Interactions via other CYP enzymes and transporter proteins cannot be excluded but are unlikely to be of clinical significance. Group: Pharmaceutical. CAS No. 1256580-46-7. Pack Sizes: 200 mg. Product ID: B0084-454466. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Alisertib | MLN8237 is a second-generation, orally bioavailable, highly selective small molecule inhibitor of the serine/threonine protein kinase Aurora A kinase with potential antineoplastic activity. Aurora kinase inhibitor MLN8237 binds to and inhibits Aurora A kinase, which may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, and inhibition of cell proliferation. Group: Pharmaceutical. CAS No. 1028486-01-2. Pack Sizes: 100 mg. Product ID: B2693-336876. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Alpelisib | Alpelisib, also known as BLY719, is an orally bioavailable phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. PI3K inhibitor BYL719 specifically inhibits PIK3 in the PI3K/AKT kinase (or protein kinase B) signaling pathway, thereby inhibiting the activation of the PI3K signaling pathway. This may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents. Group: Pharmaceutical. CAS No. 1217486-61-7. Pack Sizes: 100 mg. Product ID: B0084-457654. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| α-Amyloid Precursor Protein Modulator | α-Amyloid Precursor Protein Modulator is a cell-permeable protein kinase C (PKC) activator. It was shown to induce differentiation of hESCs into Pdx-1 expressing pancreatic progenitor cells. Group: Pharmaceutical. CAS No. 497259-23-1. Pack Sizes: 2.5 mg. Product ID: B0084-314011. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| α-Viniferin | α-Viniferin isolated from the herb of Carex humilis Leyss. It inhibits AChE activity is specific, reversible and noncompetitive,down-regulating STAT-1-inducible inflammatory genes via inhibiting ERK-mediated STAT-1 activation in IFN-gamma-stimulated macrophages. Uses: Anti-inflammatory activity; antifungal; inhibits protein kinase c; inhibits prostaglandin h2 synthase carex humilis. Group: Pharmaceutical. CAS No. 62218-13-7. Pack Sizes: 1 mg. Product ID: NP4646. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| AR-A014418 | AR-A014418 is an ATP-competitive inhibitor of glycogen synthase kinase 3β (GSK-3β), a serine/threonine protein kinase involved in multiple diseases including Alzheimer's disease and type 2 diabetes. Group: Pharmaceutical. CAS No. 487021-52-3. Pack Sizes: 25 mg. Product ID: B0084-258809. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| AVL-292 | AVL-292, also known as CC-292, is an orally bioavailable, selective inhibitor of Bruton's agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity. Upon administration, AVL-292 targets and covalently binds to BTK, thereby preventing its activity. Uses: Protein kinase inhibitors. Group: Pharmaceutical. CAS No. 1202757-89-8. Pack Sizes: 1 g. Product ID: B2693-462475. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Axitinib | Axitinib (AG013736) is a tyrosine kinase inhibitor developed by Pfizer. Axitinib is a tyrosine kinase inhibitor that blocks the activation of VEGFR1, VEGFR2, VEGFR3, c-kit, and PDGFRβ (IC50 = 1.2, 0.25, 0.29, 1.7, and 1.6 nM, respectively). It has been shown to significantly inhibit growth of breast cancer in animal (xenograft) models. Uses: Protein kinase inhibitors. Group: Pharmaceutical. CAS No. 319460-85-0. Pack Sizes: 5 g. Product ID: NP3631. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| AZD-5363 | AZD-5363 is an orally available inhibitor of the serine/threonine protein kinase AKT (protein kinase B) with potential antineoplastic activity. AZD-5363 binds to and inhibits all AKT isoforms. This agent may be used as monotherapy or combination therapy for a variety of human cancers. Group: Pharmaceutical. CAS No. 1143532-39-1. Pack Sizes: 10 mg. Product ID: B2693-457058. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Brigatinib | Brigatinib, also known as AP-26113, is an orally active, potent and selective dual ALK/EGFR inhibitor. AP26113 is an orally bioavailable inhibitor of anaplastic lymphoma kinase (ALK; IC50 < 100 nM in Ba/F3 cells). AP26113 binds to and inhibits ALK kinase and ALK fusion proteins as well as EGFR and mutant forms. It blocks ALK activity and reduces growth in neuroblastoma cells, mouse xenograft, and Drosophila model systems harboring constitutively active ALK variants. Group: Pharmaceutical. CAS No. 1197953-54-0. Pack Sizes: 1 g. Product ID: B0084-470820. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| BX-795 | 3-Phosphoinositide-dependent protein kinase 1 (PDK1) is a serine-threonine kinase that phosphorylates and activates a range of other kinases, including PKB, PKA, and certain isoforms of PKC. BX795 is a potent and specific PDK1 inhibitor with IC50 of 6 nM, which is 140- and 1600-fold more selective than PKA and PKC. It is also a potent and relatively specific inhibitor of TBK1 with IC50 of 6 nM and IKK? with IC50 of 41 nM. Group: Pharmaceutical. CAS No. 702675-74-9. Pack Sizes: 25 mg. Product ID: B0084-194478. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| C16 Ceramide | C16 ceramide is an endogenous ceramide, generated by ceramide synthase 6 (CerS6), that acts as a lipid second messenger to regulate apoptosis and stress signaling. It has also been found to activate NF-κB and PKCζ3. Uses: A predominant, rather hydrophobic natural ceramide. activates a cytosolic serine/threonine protein phosphatase in t9 cells; induces egf receptor phosphorylation in a-431 cells; stimulates ceramide-activated protein kinase. Group: Pharmaceutical. CAS No. 24696-26-2. Pack Sizes: 100 mg. Product ID: B1370-059982. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Caftaric acid | Caftaric acid is a natural compound found in the juice of grapes. It is an inhibitor of the protein-protein interactions mediated by the Src-family kinases. Uses: Used in cancer therapy as an anticancer drug. Group: Pharmaceutical. CAS No. 67879-58-7. Pack Sizes: 250 mg. Product ID: B2703-075022. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Calcineurin substrate | Calcineurin substrate is a peptide from the regulatory RII subunit of cAMP-dependent protein kinase. Group: Pharmaceutical. CAS No. 113873-67-9. Pack Sizes: 5 mg. Product ID: BAT-006181. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Chelerythrine | Chelerythrine is a benzophenanthridine alkaloid extracted from the plant Greater celandine (Chelidonium majus). It is a potent, selective, and cell-permeable protein kinase C inhibitor. It is also the major active natural product found in the plant Zanthoxylum clava-herculis, exhibiting anti-bacterial activity against Staphylococcus aureus. Chelerythrine inhibits the BclXL-Bak BH3 peptide binding with IC50 of 1.5 μM and displaces Bax from BclXL. Chelerythrine triggers apoptosis and autophagy. Uses: Antibacterial agent. Group: Pharmaceutical. CAS No. 34316-15-9. Pack Sizes: 50 mg. Product ID: NP0509. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Chelerythrine chloride | Chelerythrine is a cell-permeable inhibitor of protein kinase C (IC50 = 660 nM) with a wide range of biological activities. Group: Pharmaceutical. CAS No. 3895-92-9. Pack Sizes: 50 mg. Product ID: BBF-04087. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Chrysophanol | Chrysophanic acid (Chrysophanol) is a natural anthraquinone with anticancer activity in EGFR-overexpressing SNU-C5 human colon cancer cells. Chrysophanic acid preferentially blocked proliferation in SNU-C5 cells but not in other cell lines (HT7, HT29, KM12C, SW480, HCT116 and SNU-C4) with low levels of EGFR expression. Chrysophanic acid treatment in SNU-C5 cells inhibited EGF-induced phosphorylation of EGFR and suppressed activation of downstream signaling molecules, such as AKT, extracellular signal-regulated kinase (ERK) and the mammalian target of rapamycin (mTOR)/ribosomal protein S6 kinase (p70S6K). Chrysophanic acid (80 and 120 μm) significantly blocked cell proliferation when combined with the mTOR inhibitor, rapamycin. These findings offer the first evidence of anticancer activity for chrysophanic acid via EGFR/mTOR mediated signaling transduction pathway. Chrysophanol is a natural compound found in the roots and rhizomes of Rheum palmatum L. It can be used in cosmetics material. Uses: Anti-inflammatory. Group: Pharmaceutical. CAS No. 481-74-3. Pack Sizes: 1 g. Product ID: NP0901. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| CL-387785 | CL-387785, also known as EKI-785, is an irreversible inhibitor of EGF-receptor (EGFR) kinase activity in vivo (IC50 = 250-490 pM). CL-387785 covalently bound to EGF-R. It also specifically inhibited kinase activity of the protein (IC50 = 370+/-120 pM), blocked EGF-stimulated autophosphorylation of the receptor in cells (ic50 approximately 5 nM), inhibited cell proliferation (IC50 = 31-125 nM) primarily in a cytostatic manner in cell lines that overexpress EGF-R or c-erbB-2, and profoundly blocked the growth of a tumor that overexpresses EGF-R in nude mice (when given orally at 80 mg/kg/day for 10 days, daily). CL-387,785 is useful for studying the interaction of small molecules with EGF-R and may have clinical utility. Uses: Protein kinase inhibitors. Group: Pharmaceutical. CAS No. 194423-06-8. Pack Sizes: 50 mg. Product ID: B0084-458793. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| CZ415 | CZ415 is a highly selective potent mTOR inhibitor with little activity on other lipid and protein kinases with efficacy in a collagen induced arthritis model and exhibits excellent cell permeability. In the issue, Bergamini et al., who has identified CZ415, confirmed with its extraordinary selectivity, drug-like properties and proven efficacy in vivo, CZ415 represents an ideal molecule for the pharmacological investigation of mTOR pathophysiological role in vivo. Assessed in dose response format from HEK293T cells after treatment with CZ415: 1. inhibition of S6RP (downstream of mTORC1) phosphorylation in HEK293T: IC50 = 14.5 nM; 2. inhibition of Akt (mTORC2 substrate) phosphorylation in HEK293T: IC50 = 14.8 nM; 3. inhibition of IFNγ release in stimulated human whole blood: IC50 = 226 nM. Group: Pharmaceutical. CAS No. 1429639-50-8. Pack Sizes: 5 mg. Product ID: B0084-474821. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Dasatinib | Dasatinib, also known as BMS-354825, is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes. Group: Pharmaceutical. CAS No. 302962-49-8. Pack Sizes: 25 g. Product ID: NP3264. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| D-erythro-Sphingosine | D-erythro-Sphingosine is a natural isomer of sphingosine and acts as an inhibitor of protein kinase C and calmodulin-dependent enzymes with no effects on protein kinase A or myosin light chain kinase. It may stimulate mast cells by activation of protein kinase C. Group: Pharmaceutical. CAS No. 123-78-4. Pack Sizes: 250 mg. Product ID: B2693-162633. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Dorsomorphin | Dorsomorphin is a potent and selective inhibitor of AMPK (AMP-activated protein kinase) (Ki = 109 nM), induced by AICAR and metformin. It also inhibits bone morphogenetic protein (BMP) receptors including BMPR-IA (ALK3) and BMPR-IB (ALK6). Dorsomorphin can induce myocardial differentiation in mouse embryonic stem cells (mESCs). Uses: Protein kinase inhibitors. Group: Pharmaceutical. CAS No. 866405-64-3. Pack Sizes: 10 mg. Product ID: B0084-462934. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Dracorhodin perchlorate | Dracorhodin perchlorate can inhibit high glucose-induced serum and glucocorticoid induced protein kinase 1 (SGK1) and fibronectin (FN) expression in human mesangial cells, and this may be a part of the mechanism of preventing and treating renal fibrosis of DN. Group: Pharmaceutical. CAS No. 125536-25-6. Pack Sizes: 100 mg. Product ID: B1370-252868. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Encorafenib | Encorafenib, also known as LGX-818, is an orally available Raf kinase inhibitor with potential antineoplastic activity. LGX818 specifically inhibits Raf kinase, a serine/threonine enzyme in the RAF/mitogen-activated protein kinase kinase (MEK)/extracellular signal-related kinase (ERK) signaling pathway. By inhibiting the activation of the RAF/MEK/ERK signaling pathway, the administration of LGX818 may result in a decrease in proliferation of tumor cells. The Raf mutation BRAF V600E is frequently upregulated in a variety of human tumors and results in the constitutive activation of the RAF/MEK/ERK signaling pathway that regulates cellular proliferation and survival. Group: Pharmaceutical. CAS No. 1269440-17-6. Pack Sizes: 150 mg. Product ID: B0084-462563. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Entrectinib | Entrectinib (RXDX-101) is an orally bioavailable pan-TrkA/B/C, ROS1 and ALK inhibitor with IC50 ranging between 0.1 and 1.7 nM. Phase 2. Uses: Protein kinase inhibitors. Group: Pharmaceutical. CAS No. 1108743-60-7. Pack Sizes: 250 mg. Product ID: B0084-470812. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Enzastaurin | Enzastaurin is a protein kinase C beta inhibitor with 6- to 20-fold selectivity against PKCα, PKCγ and PKC&epsilon. Binding to the ATP-binding site, enzastaurin selectively inhibits protein kinase C beta, an enzyme involved in the induction of vascular endothelial growth factor (VEGF)-stimulated neo-angiogenesis. This agent may decrease tumor blood supply and so tumor burden. Group: Pharmaceutical. CAS No. 170364-57-5. Pack Sizes: 200 mg. Product ID: B0084-085618. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| ETC-1002 | ETC-1002 is a novel, first-in-class, orally available, once-daily LDL-C lowering small molecule and is activator of hepatic AMP-activated protein kinase (AMPK). It also has potent inhibitory activity against hepatic ATP-citrate lyase. Group: Pharmaceutical. CAS No. 738606-46-7. Pack Sizes: 250 mg. Product ID: B0084-463320. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Ethyl (4-((2-(Methylcarbamoyl)pyridin-4-yl)oxy)phenyl)carbamate | An impurity of Sorafenib. Sorafenib is a small inhibitor of several tyrosine protein kinases, such as VEGFR, PDGFR and Raf family kinases, for the treatment of primary kidney cancer, advanced primary liver cancer and radioactive iodine resistant advanced thyroid carcinoma. Group: Pharmaceutical. CAS No. 2206827-12-3. Pack Sizes: 100 mg. Product ID: B2694-479756. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| (E/Z)-Endoxifen | One of the impurities of Tamoxifen, which is an estrogen response modifier as well as protein kinase C inhibitor. Group: Pharmaceutical. CAS No. 110025-28-0. Pack Sizes: 10 mg. Product ID: B2694-257357. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Fasudil hydrochloride | Fasudil HCl, a 5-isoquinolinesulfonamide derivative, is a highly selective Rho-associated protein kinase inhibitor that might have a rate in romoting the recovery of neurological function, reducing clinical symptoms and the morbidity. Uses: Fasudil hcl, a 5-isoquinolinesulfonamide derivative, is a highly selective rho-associated protein kinase inhibitor that might have a rate in romoting the recovery of neurological function, reducing clinical symptoms and the morbidity. Group: Pharmaceutical. CAS No. 105628-07-7. Pack Sizes: 1 g. Product ID: B2693-053715. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Ganoderiol F | Lansiumarin C is a natural coumarin found in the branches of Clausena lansium. and found to induce senescence of cancer cell lines, it induces growth arrest of cancer cell lines HepG2, Huh7 and K562; activation of the mitogen-activated protein kinase EKR and up-regulation of cyclin-dependent kinase inhibitor p16 were found in early stages of Ganoderiol F treatment and were presumed to cause cell-cycle arrest and trigger premature senescence of HepG2 cells; suggests that the growth-arrest and senescence induction capability on cancer cells suggest anticancer potential of Ganoderiol F. It could be developed further as both anti-HIV and antimalaria.In Compared to plasmepsin I, ganoderiol-F is higher towards HIV-1 protease. Uses: Anti-inflammatory; anti-hiv. Group: Pharmaceutical. CAS No. 114567-47-4. Pack Sizes: 1 mg. Product ID: NP6829. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| GDC-0994 | GDC-0994, also known as RG7842, is an orally available inhibitor of extracellular signal-regulated kinase (ERK), with potential antineoplastic activity. Upon oral administration, GDC-0994 inhibits both ERK phosphorylation and activation of ERK-mediated signal transduction pathways. This prevents ERK-dependent tumor cell proliferation and survival. The mitogen-activated protein kinase (MAPK)/ERK pathway is upregulated in a variety of tumor cell types and plays a key role in tumor cell proliferation, differentiation and survival. Uses: Antineoplastic agents. Group: Pharmaceutical. CAS No. 1453848-26-4. Pack Sizes: 50 mg. Product ID: B2693-462528. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Genistein | Genistein, a phytoestrogen found in soy products, is a highly specific inhibitor of protein tyrosine kinase (PTK) which blocks the mitogenic effect mediated by EGF on NIH-3T3 cells with IC50 of 12μM or by insulin with IC50 of 19 μM. Genistein is developed to be an antitumor agent. Genistein has antioxidant effect, it can be used in cosmetics material. It is a plant polyphenol that can inhibit tyrosinase, block melanin synthesis, reduce skin pigment intensity, absorb UV, prevent photoaging, reduce sun damage and age spot formation, and whiten and lighten spots. It also has the anti-glycation and antibacterial effect, can effectively improve skin tone and skin texture, prevent the generation of age spots, remove red bloodlines, and improve skin blood microcirculation. Uses: Antitumor agent. Group: Pharmaceutical. CAS No. 446-72-0. Pack Sizes: 5 g. Product ID: BBF-01840. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Ginsenoside F4 | Ginsenoside F4 is extracted from the root of Panax ginseng C. A. Mey. It has inhibitory effect on human lymphocytoma JK cell by inducing its apoptosis. It was found to strongly inhibit activation of p38 mitogen-activated protein kinase in signal transduction pathways. Group: Pharmaceutical. CAS No. 181225-33-2. Pack Sizes: 10 mg. Product ID: B0005-454183. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Ginsenoside Rb1 | A major bioactive component of panax ginseng that promotes neurotransmitter release by modulating phosphorylation of synapsins through a cAMP-dependent protein kinase pathway. It has been reported to display immunostimulatory and anticancer effects. It has anti-aging effect, can be used in health products. Uses: Anti-oxidative damage,immunostimulatory,anticancer. Group: Pharmaceutical. CAS No. 41753-43-9. Pack Sizes: 100 mg. Product ID: NP6991. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Glutathione EP Impurity C | Oxiglutatione is a stabilized formulation of disodium glutathione disulfide (GSSG; oxidized glutathione) and cisplatin (1000:1) with potential chemoprotective and immunomodulating activities. Mimicking endogenous GSSG, Oxiglutatione acts as a competitive substrate for gamma-glutamyl-transpeptidase (GGT), which may result in the S-glutathionylation of proteins, predominantly actin, a redox stress on endoplasmic reticulum (ER), and ER stress-induced apoptosis. S-glutathionylation may be stimulated by reactive oxygen species (ROS) liberated by an oxiglutatione-induced increase in GGT activity. Oxiglutatione may also induce phosphorylation of proteins such as ERK and p38, two kinases that play critical regulatory roles in cell proliferation and apoptosis. The cisplatin component of this agent does not provide an effective therapeutic concentration of cisplatin in vivo. Group: Pharmaceutical. CAS No. 27025-41-8. Pack Sizes: 25 g. Product ID: B0084-064728. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| GSK 2606414 | GSK 2606414 is a potent and selective PERK inhibitor that suppresses PERK activation in cells and inhibits the growth of a human tumor xenograft in mice. Protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) is activated in response to a variety of endoplasmic reticulum stresses implicated in numerous disease states. Evidence that PERK is implicated in tumorigenesis and cancer cell survival stimulated our search for small-molecule inhibitors. Group: Pharmaceutical. CAS No. 1337531-36-8. Pack Sizes: 100 mg. Product ID: B0084-462365. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| GSK-461364 | GSK-461364 is a Polo-like kinase 1 inhibitor, is also a small molecule Polo-like kinase 1 (PLK1) inhibitor with potential antineoplastic activity. Polo-like kinase 1 inhibitor GSK461364 selectively inhibits Plk1, inducing selective G2/M arrest followed by apoptosis in a variety of tumor cells while causing reversible cell arrest at the G1 and G2 stage without apoptosis in normal cells. Plk1, named after the polo gene of Drosophila melanogaster, is a serine/threonine protein kinase involved in regulating mitotic spindle function in a non-ATP competitive manner. Group: Pharmaceutical. CAS No. 929095-18-1. Pack Sizes: 10 mg. Product ID: B0084-307746. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| GYY-4137 Morpholine salt | GYY-4137 Morpholine salt is a novel water-soluble and slow releasing Hydrogen sulfide(H2S) donor. It protects against myocardial ischemia and reperfusion injury by attenuating oxidative stress and apoptosis in rats. It inhibits the inflammatory response by suppressing the activation of nuclear factor-kappa B and mitogen-activated protein kinases in Coxsackie virus B3-infected rat cardiomyocytes. It exhibits potent anti-cancer activity. It exhibits vasodilator and antihypertensive activity in rats, in either the acute or chronic hypertension models. It does not influence vascular smooth muscle cell viability in culture. It also protects against endotoxic shock in rats, inhibiting tumor necrosis factor-α, interleukin (IL)-1β, and IL-6 production and reducing NF-κB activation, iNOS and cyclooxygenase-2 expression, and NO and prostaglandin E2 generation. Uses: Gyy-4137 morpholine salt inhibits the inflammatory response. it exhibits potent anti-cancer activity. it exhibits vasodilator and antihypertensive activity. Group: Pharmaceutical. CAS No. 106740-09-4. Pack Sizes: 100 mg. Product ID: B2693-272139. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Ipatasertib | Ipatasertib, also known as GDC-0068 is an orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Akt inhibitor GDC-0068 binds to and inhibits the activity of Akt in a non-ATP-competitive manner, which may result in the inhibition of the PI3K/Akt signaling pathway and tumor cell proliferation and the induction of tumor cell apoptosis. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents. Uses: Antineoplastic agents. Group: Pharmaceutical. CAS No. 1001264-89-6. Pack Sizes: 50 mg. Product ID: B2693-456282. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Isoprenaline hydrochloride | Isoprenaline is a non-selective beta-adrenergic receptor agonist, used for the treatment of bradycardia and heart block. It would increase cAMP levels and activate protein kinase A and ERK1/2 through its effect on β-adrenoceptor. Uses: The treatment of bradycardia and heart block. Group: Pharmaceutical. CAS No. 51-30-9. Pack Sizes: 50 g. Product ID: NP3260. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| JNK-IN-8 | JNK-IN-8 inhibits c-Jun phosphorylation in HeLa and A375 cells with EC50 of 486 nM and 338 nM, respectively. Uses: Protein kinase inhibitors. Group: Pharmaceutical. CAS No. 1410880-22-6. Pack Sizes: 20 mg. Product ID: B0084-463416. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| K252A | K252a, an analog of staurosporine, has been found to be a protein kinase inhibitor and exhibit antitumor activity at some extent. Group: Pharmaceutical. CAS No. 99533-80-9. Pack Sizes: 50 mg. Product ID: BBF-04182. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| KD025 | KD025 is an orally available and selective ROCK2 inhibitor with IC50 value of 60 nM and Ki value of 41 nm, respectively. It was shown to suppress adipogenesis in human adipose-derived stem cells. Uses: Protein kinase inhibitors. Group: Pharmaceutical. CAS No. 911417-87-3. Pack Sizes: 100 mg. Product ID: B0084-460389. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Ku-0063794 | KU-0063794 is an inhibitor of both mTORC1 and mTORC2 with an IC50 of approximately 10 nM, but does not suppress the activity of 76 other protein kinases or seven lipid kinases, including Class 1 PI3Ks (phosphoinositide 3-kinases) at 1000-fold higher concentrations. KU-0063794 is cell permeant, suppresses activation and hydrophobic motif phosphorylation of Akt, S6K and SGK, but not RSK (ribosomal S6 kinase), an AGC kinase not regulated by mTOR. It also inhibited phosphorylation of the T-loop Thr308 residue of Akt phosphorylated by PDK1 (3-phosphoinositide-dependent protein kinase-1). It does not affect Thr308 phosphorylation in fibroblasts lacking essential mTORC2 subunits. KU-0063794 also suppressed cell growth and induced a G1-cell-cycle arrest. KU-0063794 will be useful in delineating the physiological roles of mTOR and may have utility in treatment of cancers in which this pathway is inappropriately activated. Uses: Differentiation. Group: Pharmaceutical. CAS No. 938440-64-3. Pack Sizes: 100 mg. Product ID: B0084-100850. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Lapatinib | Lapatinib, used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM, respectively. Uses: Antineoplastic agents; protein kinase inhibitors. Group: Pharmaceutical. CAS No. 231277-92-2. Pack Sizes: 1 g. Product ID: NP3214. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Lapatinib Ditosylate | Lapatinib is a synthetic, orally-active quinazoline with potential antineoplastic activity. Lapatinib reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types. Uses: Antineoplastic agents. Group: Pharmaceutical. CAS No. 388082-77-7. Pack Sizes: 1 g. Product ID: B0084-067756. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| LDS 867 | LDS 867 is a potent and selective protein kinase D (PKD) inhibitor used in the biomedical industry for research on cancer treatment. It effectively inhibits PKD and displays anticancer activity against a range of malignancies, including breast and pancreatic cancers. LDS 867 is a valuable tool in the study of PKD signaling pathways and potential therapeutic strategies for various diseases. Group: Pharmaceutical. CAS No. 106025-71-2. Pack Sizes: 250 mg. Product ID: B2708-285552. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| LY2606368 | LY2606368 is a potent and selective ATP competitive inhibitor(IC50=1.5 nM in SW1990 cell) of the Chk1 protein kinase. Group: Pharmaceutical. CAS No. 1234015-52-1. Pack Sizes: 10 mg. Product ID: B0084-462722. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Masitinib | Masitinib is an orally bioavailable and multi-targeted protein tyrosine kinase inhibitor with potential antineoplastic activity. Group: Pharmaceutical. CAS No. 790299-79-5. Pack Sizes: 250 mg. Product ID: B0084-077384. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Melittin (honeybee) | Melittin is a polypeptide isolated from the venom of the honey bee (Apis mellifera). It inhibits protein kinase C, Ca2+/calmodulin-dependent protein kinase II, myosin light chain kinase and Na+/K+-ATPase (synaptosomal membrane). Group: Pharmaceutical. CAS No. 20449-79-0. Pack Sizes: 25 mg. Product ID: BAT-010534. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Midostaurin | Midostaurin is a multi-target protein kinase inhibitor being investigated for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). It is a semi-synthetic derivative of staurosporine, an alkaloid from the bacterium Streptomyces staurosporeus. Group: Pharmaceutical. CAS No. 120685-11-2. Pack Sizes: 20 mg. Product ID: BBF-05737. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Motesanib | Motesanib is a multikinase inhibitor that selectively targets VEGF receptors, platelet-derived growth factor receptors (PDGFRs), and Kit receptors. It also potently inhibits angiogenesis and induces regression in tumor xenografts. Uses: Protein kinase inhibitors. Group: Pharmaceutical. CAS No. 453562-69-1. Pack Sizes: 100 mg. Product ID: B0084-069090. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Motesanib Diphosphate | Motesanib Diphosphate is a potent ATP-competitive inhibitor of VEGFR1/2/3 with IC50 of 2 nM/3 nM/6 nM, respectively; similar activity against Kit, ~10-fold more selective for VEGFR than PDGFR and Ret. Uses: Protein kinase inhibitors. Group: Pharmaceutical. CAS No. 857876-30-3. Pack Sizes: 50 mg. Product ID: B0084-153042. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Mubritinib | Mubritinib, also known as TAK-165, is a protein kinase inhibitor which was under development by Takeda for the treatment of cancer. It completed phase I clinical trials (may be discontinued since 2008). Mubritinib(TAK 165) is a potent EGFR, HER2 and p34cdc2 inhibitor with IC50 of 6 nM and 0.2 μM, respectively. Mubritinib(TAK 165) also inhibits p33cdk2 and p33cdk5. Mubritinib(TAK 165) displays > 4000-fold selectivity over EGFR, FGFR, PDGFR, JAK1 and Src. Mubritinib(TAK 165) exhibits potent antiproliferative effects in ErbB2-overexpressing cancer cell lines (IC50 = 5 nM in BT474 breast cancer cells) and significantly inhibits bladder, breast and prostate cancer xenograft growth in vivo. Group: Pharmaceutical. CAS No. 366017-09-6. Pack Sizes: 50 mg. Product ID: B0084-067201. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| N-benzyl-9Z,12Z,15Z-octadecatrienamide | Utilized in the realm of biomedical study as an inhibitor of protein kinase, the synthetically derived N-benzyl-9Z,12Z,15Z-octadecatrienamide displays potent efficacy in quelling the proliferation of human cancer cells, thereby evidencing its likelihood as a front-runner in the development of cancer therapy. Group: Pharmaceutical. CAS No. 883715-18-2. Pack Sizes: 5 mg. Product ID: NP0191. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| N-Desmethyltamoxifen | N-Desmethyltamoxifen is a metabolite of tamoxifen, which is an estrogen response modifier as well as protein kinase C inhibitor. Group: Pharmaceutical. CAS No. 31750-48-8. Pack Sizes: 1 g. Product ID: B1370-107540. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| N-Desmethyl Tamoxifen HCl | One of the impurities of Tamoxifen, which is an estrogen response modifier as well as protein kinase C inhibitor. Group: Pharmaceutical. CAS No. 15917-65-4. Pack Sizes: 100 mg. Product ID: B1370-260466. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Neochinulin A | Neoechinulin A is isolated from Aspergillus chevalieri. It may block the phosphorylation of mitogen-activated protein kinase (MAPK) molecule p38, apoptosis signal-regulating kinase 1 (ASK-1) and nuclear translocation of nuclear factor-κB (NF-κB) p65 and p50 subunits. Uses: Antioxidant; anti-inflammatory; antioxidant/anti-nitration. Group: Pharmaceutical. CAS No. 51551-29-2. Pack Sizes: 1 mg. Product ID: NP0376. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Netarsudil Mesylate | Netarsudil, also known as AR-11324, is a Rho-associated protein kinase inhibitor. Netarsudil is potential useful for treating glaucoma and?/or reducing intraocular pressure. Group: Pharmaceutical. CAS No. 1422144-42-0. Pack Sizes: 10 mg. Product ID: B0084-475227. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
| Nilotinib monohydrochloride monohydrate | Nilotinib monohydrochloride monohydrate is an orally bioavailable aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. It binds to and stabilizes the inactive conformation of the kinase domain of the Abl protein of the Bcr-Abl fusion protein, resulting in the inhibition of the Bcr-Abl-mediated proliferation of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) cells. It also inhibits the receptor tyrosine kinases platelet-derived growth factor receptor (PDGF-R) and c-kit, a receptor tyrosine kinase mutated and constitutively activated in most gastrointestinal stromal tumors (GISTs). Uses: Tyrosine kinase inhibitors. Group: Pharmaceutical. CAS No. 923288-90-8. Pack Sizes: 100 mg. Product ID: B0084-182383. Molecular formula: Custom synthesis is available. Send your inquiries for more information. | London |
Our database is helping our users find suppliers everyday.
